Medtronic plc 8-K

What Happened

• Medtronic plc filed an 8-K on May 18, 2026, announcing that Brett Wall will depart his role as Executive Vice President and President, Neuroscience Portfolio. Dr. Kweli Thompson, currently Senior Vice President and President, Cardiac Rhythm Management, will become Executive Vice President and President, Neuroscience Portfolio effective June 1, 2026.
• Mr. Wall will remain employed through September 1, 2026, to assist with the transition.

Key Details

• Filing date: May 18, 2026 (Form 8-K).
• Effective date of new appointment: June 1, 2026 (Dr. Kweli Thompson).
• Transition period: Brett Wall remains an employee until September 1, 2026.
• Severance: Mr. Wall is entitled to severance payments and benefits consistent with Medtronic’s executive severance practices as described in the company’s 2025 Proxy Statement.

Why It Matters

• This is a material leadership change for Medtronic’s Neuroscience Portfolio, which could affect strategy and execution within that business unit. The company has named an internal leader (Dr. Thompson) and arranged a transition period through September 1, 2026, which supports continuity.
• Investors should note the change for assessments of management stability and may watch for any related updates in future filings, earnings reports, or communications about portfolio strategy and performance.